Molecular Templates (NASDAQ:MTEM) issued its earnings results on Monday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02), Fidelity Earnings reports. The firm had revenue of $5.45 million during the quarter, compared to analysts’ expectations of $6.00 million. Molecular Templates had a negative return on equity of 9.14% and a negative net margin of 42.15%.
Shares of Molecular Templates stock traded down $0.04 on Tuesday, reaching $4.97. 1,023 shares of the company traded hands, compared to its average volume of 84,952. Molecular Templates has a 52 week low of $3.19 and a 52 week high of $8.77. The business has a 50 day moving average of $7.09. The stock has a market cap of $190.46 million, a price-to-earnings ratio of -4.87 and a beta of 2.77. The company has a quick ratio of 3.24, a current ratio of 3.24 and a debt-to-equity ratio of 0.14.
Several research analysts have issued reports on the stock. BidaskClub cut shares of Molecular Templates from a “hold” rating to a “sell” rating in a report on Friday, July 26th. TheStreet lowered Molecular Templates from a “c-” rating to a “d” rating in a research note on Monday, August 5th. ValuEngine lowered Molecular Templates from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Molecular Templates from a “buy” rating to a “hold” rating in a research note on Wednesday, June 5th. Finally, Cowen reaffirmed a “buy” rating on shares of Molecular Templates in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $13.58.
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma.
Featured Article: How to Invest in a Bull Market
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.